[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581475":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":43,"collaborators":20,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":20,"enrollmentInfo":57,"targetDuration":20,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University of Sao Paulo General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Telemedicine-Based Intervention to Improve Adherence in PAH Patients on Oral Therapy","EXPERIMENTAL","Participants will receive biweekly teleconsultations over 24 weeks, as part of a structured telemedicine intervention to support medication adherence in patients with pulmonary arterial hypertension (PAH) on stable oral therapy. Each teleconsultation is delivered by a trained healthcare professional and includes adherence assessment, identification of barriers, guidance on side effects, educational reinforcement, and motivational support. The intervention does not change the medical regimen but aims to optimize adherence and clinical outcomes through remote follow-up. Data will be collected at baseline and at 24 weeks to evaluate changes in adherence (Martín-Bayarre-Grau scale), functional class, 6-minute walk distance, BNP levels, risk stratification (COMPERA 2.0, REVEAL Lite), hospitalizations, mortality, and quality of life (CAMPHOR).",[13],"Behavioral: Telemedicine-Based Adherence Support",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BEHAVIORAL","Telemedicine-Based Adherence Support","The intervention consists of biweekly teleconsultations for six months, conducted by healthcare professionals, focusing on medication adherence, patient education, side effect management, and remote support for individuals with pulmonary arterial hypertension (PAH). Patients will receive structured guidance on treatment adherence, tailored counseling, and real-time problem-solving strategies. The goal is to improve adherence to oral PAH therapy and enhance clinical outcomes compared to standard care.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Caio Fernandes, PhD","CONTACT","+55 11 2661-1548","caio.cesar@hc.fm.usp.br",[28],{"facility":29,"status":30,"city":31,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"InCor - Universidade de São Paulo","RECRUITING","São Paulo","05048000","Brazil","BR",{"type":36,"coordinates":37},"Point",[38,39],-46.63611,-23.5475,{"lat":39,"lon":38},[42],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Caio Júlio César dos Santos Fernandes","Principal Investigator","100581475","improving-adherence-to-pulmonary-arterial-hypertension-treatment-with-telemedicine-and-patient-guidance-100581475",false,"NCT06850792","imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce","imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce - A Multicenter Pre- and Post-intervention Evaluation Study","OPENLINE","Inclusion Criteria:\n\n* Adults aged ≥18 years diagnosed with pulmonary arterial hypertension (PAH) (Group 1 of the WHO classification).\n* Stable oral PAH therapy (including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, or prostacyclin pathway agents) for at least four weeks prior to enrollment.\n* Ability to participate in remote teleconsultations (access to a phone or internet).\n* Signed informed consent agreeing to study participation.\n\nExclusion Criteria:\n\n* Severe cognitive impairment or psychiatric disorders that could affect adherence or study participation.\n* Inability to communicate via phone or telemedicine due to technical or personal constraints.\n* Concurrent participation in another interventional clinical trial that could interfere with outcomes.\n* Life expectancy \\\u003C6 months due to any condition unrelated to PAH.\n* Pregnancy or breastfeeding.","ALL","18 Years",{"count":58,"type":59},61,"ESTIMATED","INTERVENTIONAL",[62],"NA","Pulmonary arterial hypertension (PAH) is a progressive condition with high morbidity, frequent hospitalizations, and risk of right heart failure. Despite advances in treatment, poor adherence remains a major challenge. This randomized controlled study assesses whether remote monitoring can improve treatment adherence, clinical outcomes, and side effect management in PAH patients on oral therapy.",[65,66,67],"Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)","Pulmonary Arterial Hypertension (PAH)","Pulmonary Arterial Hypertension",[66,69,70,71,72,73,74,75,76,77,78,79,80,81,82],"Medication Adherence","Telemedicine","Patient Education","Remote Monitoring","Digital Health Intervention","Randomized Controlled Trial (RCT)","Multicenter Study","COMPERA 2.0","REVEAL Lite","Six-Minute Walk Test (6MWT)","Quality of Life","CAMPHOR Questionnaire","Martín-Bayarre-Grau (MBG) Scale","Oral Therapy for PAH","2025-06-05",{"date":85,"type":86},"2025-06-10","ACTUAL",{"date":88,"type":86},"2025-05-07",{"date":90,"type":59},"2028-04",{"name":5,"class":6},1]